DDInter915 DDInter1897
Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. Indacaterol is provided as its maleate salt form. Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed.
Ulipristal is a selective progesterone receptor modulator used for the purposes of emergency contraception (Ella) and for the treatment of uterine fibroids (Fibristal). It is a derivative of 19-norprogesterone and has both antagonistic and partial agonist activity at the progesterone receptor. It also binds to glucocorticoid receptor, however compared to mifepristone (a progesterone receptor antagonist), ulipristal is more tolerable and has lower glucocorticoid activity and better binding affinity. Ulipristal is currently recommended as first line therapy for emergency contraception, due to improved efficacy and similar side effect profile as compared to the traditional use of levonorgestrel or the Yuzpe regimen. The exact mechanism of action for ulipristal is still currently debated, though there is evidence that it functions by inhibiting ovulation. A recent systematic review proclaimed that the majority of available evidence demonstrates an inhibitory effect on ovulation rather than a post-fertilization effect on the endometrium, which has been heavily debated due to ethical concerns related to abortion (Rosato et al, 2016). Nevertheless, current and ongoing research into the agent's mechanism of action as an emergency contraceptive continue to provide potentially plausible evidence that ulipristal may, in fact, elicit activity on the endometrium that prevents embryo implantation [A175372, A175375, A175378].
Indacaterol {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Fluconazole
Fluconazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ulipristal
Indacaterol {u} (Compound) causes {v} (Side Effect) Hypersensitivity
Hypersensitivity {u} (Side Effect) is caused by {v} (Compound) Fluconazole
Fluconazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ulipristal
Indacaterol {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Rivaroxaban
Rivaroxaban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ulipristal
Indacaterol {u} (Compound) causes {v} (Side Effect) Malnutrition
Malnutrition {u} (Side Effect) is caused by {v} (Compound) Rifaximin
Rifaximin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ulipristal
Indacaterol {u} (Compound) treats {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Zafirlukast
Zafirlukast {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ulipristal
Indacaterol {u} (Compound) binds {v} (Gene) ADRB2
ADRB2 {u} (Gene) is upregulated by {v} (Compound) Nilotinib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ulipristal
Indacaterol {u} (Compound) causes {v} (Side Effect) Malnutrition
Malnutrition {u} (Side Effect) is caused by {v} (Compound) Afatinib
Afatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ulipristal
Indacaterol {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Afatinib
Afatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ulipristal
Indacaterol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Fluconazole (Compound) and Fluconazole may cause a minor interaction that can limit clinical effects when taken with Ulipristal
Indacaterol (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Fluconazole (Compound) and Fluconazole may cause a minor interaction that can limit clinical effects when taken with Ulipristal
Indacaterol (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Rivaroxaban (Compound) and Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Ulipristal
Indacaterol (Compound) causes Malnutrition (Side Effect) and Malnutrition (Side Effect) is caused by Rifaximin (Compound) and Rifaximin may cause a moderate interaction that could exacerbate diseases when taken with Ulipristal
Indacaterol (Compound) treats asthma (Disease) and asthma (Disease) is treated by Zafirlukast (Compound) and Zafirlukast may cause a minor interaction that can limit clinical effects when taken with Ulipristal
Indacaterol (Compound) binds ADRB2 (Gene) and ADRB2 (Gene) is upregulated by Nilotinib (Compound) and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ulipristal
Indacaterol (Compound) causes Malnutrition (Side Effect) and Malnutrition (Side Effect) is caused by Afatinib (Compound) and Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Ulipristal
Indacaterol (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Afatinib (Compound) and Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Ulipristal